QR-6401
oral, macrocyclic CDK2 inhibitor robust activity in ovarian cancer xenograft models AI generative modeling + opt. ACS. Med. Chem. Lett., February 8, 2023 Regor Therapeutics Group, Shanghai, CN
Molecules of the Month - February 2023
oral, macrocyclic CDK2 inhibitor robust activity in ovarian cancer xenograft models AI generative modeling + opt. ACS. Med. Chem. Lett., February 8, 2023 Regor Therapeutics Group, Shanghai, CN
Molecules of the Month - February 2023